Document is current
Any future updates will be listed below
-
Authors
Lencz, Todd https://orcid.org/0000-0001-8586-338X
Moyett, Ashley
Argyelan, Miklos https://orcid.org/0000-0002-7254-1776
Barber, Anita D.
Cholewa, John
Birnbaum, Michael L.
Gallego, Juan A. https://orcid.org/0000-0003-4900-7812
John, Majnu
Szeszko, Philip R.
Robinson, Delbert G. https://orcid.org/0000-0001-6606-4507
Malhotra, Anil K.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH108654, P50 MH080713, R21 MH101746, R21 MH101746, R21 MH101746)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 13 June 2022
Revised: 5 September 2022
Accepted: 21 September 2022
First Online: 5 October 2022
Competing interests
: DGR has been a consultant to Acadia, Advocates for Human Potential, Amalyx, American Psychiatric Association, C4 Innovations, Costello Medical Consulting, Health Analytics, Innovative Science Solutions, Janssen, Lundbeck, Neurocrine, Neuronix, Otsuka, Teva, and US World Meds and has received research support from Otsuka. DGR also provides training and consultation about implementing NAVIGATE treatment that can include compensation. AKM has been a consultant to Genomind, InformedDNA, and Janssen. MLB is a consultant for HearMe and Northshore Therapeutics. JAG has served as a consultant to Alkermes. No other authors report competing interests.
